fashion -WSS

fashion

author：explore 2025-09-29 01:07:31 - browse：57363

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

focus

WSS

H5N1 bird flu outbreak: Second human case reported, in Michigan

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Ransomware attacks on hospitals: Study outlines patient impact

Childhood cancer progress stalls for Black, Hispanic kids: Report

H5N1 bird flu outbreak: Second human case reported, in Michigan

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Cue Health, Covid

Tori Bowie and the unacceptable rates of Black maternal death

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Heart attack and stroke risk calculators need revising

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Virginia high school admissions case could be legal follow

Biogen joins immunology wave with $1.15 billion acquisition of HI

State Dept. review finds Biden bears some blame for Afghanistan failures

World's first CRISPR

entertainment

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Poor hospice wound care hurts patients and families

Why medical students are struggling with mental health

Ransomware attacks on hospitals: Study outlines patient impact

PBM reforms clear House panel

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

hotspot

hotspot

focus

hotspot